[Efficacy analysis of tumor necrosis factor inhibitors in the treatment of chronic recurrent multifocal osteomyelitis].
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
To evaluate the efficacy and safety of tumor necrosis factor inhibitors (TNFi) in treating chronic recurrent multifocal osteomyelitis (CRMO) in Chinese children.A retrospective cohort study was conducted on 52 pediatric patients with chronic recurrent multifocal osteomyelitis (CRMO) diagnosed between June 2018 and June 2025 at the Department of Rheumatology and Immunology, Capital Center for Children's Health, Capital Medical University, and its cooperative institutions (Dept. of Pediatrics, First Affiliated Hospital of Zhengzhou Medical University; Dept. of Pediatrics, Affiliated Hospital of Inner Mongolia Medical University). Patients were grouped by TNFi administration during the disease course: TNFi-treated group (n=19) and non-TNFi-treated group (n=33). Baseline demographics, laboratory findings, imaging data, treatment responses, and adverse events were collected via the electronic medical record system and outpatient follow-up records. Disease activity was assessed using the modified Physician Global Assessment (PGA) score, and efficacy and recurrence risk were compared between groups with Kaplan-Meier curves. The results showed that the TNFi group (n=19) had significantly higher proportions of spinal involvement (8/19 vs. 2/33, χ2=12.683, P=0.003), bone destruction (16/19 vs. 8/33, χ2=26.745, P<0.001), and gastrointestinal involvement (6/19 vs. 2/33, χ2=4.267, P=0.04) than the non-TNFi group (n=33), while no significant differences were found between the two groups in complete remission rate (13/19 vs. 24/33, χ2=0.002, P=0.99), recurrence rate (9/19 vs. 8/33, χ2=1.543, P=0.21), or time to recurrence (11.75±6.22 months vs. 15.31±11.40 months, t=0.952, P=0.316); additionally, the non-TNFi group had significantly higher interleukin-6 (IL-6) levels [8.55(4.78, 20.41) pg/ml vs. 4.91(2.40, 12.84) pg/ml, Z=2.418, P=0.015], and infection (6/19 vs. 9/33, χ2=0.198, P=0.656) and liver function abnormalities (2/19 vs. 3/33, χ2=0.000, P=1.000) were comparable between the two groups, with all cases being mild and manageable. In conclusion,TNFi demonstrates significant efficacy and favorable safety in CRMO children with spinal lesions, bone destruction, or gastrointestinal involvement, and may be one of the effective treatment options for refractory cases.